KROMATID Highlights Genomic Instability Benchmarking Work in Gene-Edited Cell Therapies

According to a recent LinkedIn post from KROMATID, the company is featuring new work on chromosome-scale benchmarks for genomic instability in gene-edited cell therapies at the ASGCT meeting. The presentation by VP of Platform Erin Cross is positioned within the Analytics and Assay Development – Biosafety track and focuses on high-depth cytogenetic analysis.

The post suggests this research is intended to help transition genomic data use in cell and gene therapy from largely descriptive outputs to more predictive, decision-oriented frameworks. For investors, progress toward standardized benchmarks and more robust biosafety analytics could enhance KROMATID’s value proposition with biopharma partners, potentially supporting adoption of its platform in regulatory-sensitive therapeutic development workflows.